Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Elite Pharmaceuticals
Opioid antagonist product developed for abuse resistance
May 14th, 2003
Elite Pharmaceuticals, Inc., (ELI) announced that its wholly owned subsidiary Elite Laboratories, Inc., has developed an opioid antagonist product to be used with oxycodone and other opioids to minimize the abuse potential of the opioids. A patent application has been filed for this product and the phase I trial is expected to begin shortly. Elite has previously announced that it has developed a once-a-day oxycodone product. That product has completed a phase I study that showed comparable bioavailability to the twice-daily reference product that is currently marketed. The currently marketed reference product has U.S. sales exceeding $1...
Source: Biotech Week (2003-05-14)
|
